It seems that soon we could have a fifth vaccine against Covid-19. Is about Novavax, from the American biotechnology company of the same name and which is 100% effective against moderate and severe cases. Also, a good part It will be produced at the company’s factory in O Porriño (Pontevedra).
With this information, it is important to note that all European production will be carried out here and it is the first vaccine against the coronavirus to be produced in Spain.
What is its development?
Its development is different from the Covid-19 vaccines approved so far. And the same technique is used that is already used in vaccines against other diseases, such as hepatitis A and B. According to agencies, it contains purified protein antigen and cannot replicate or cause disease.
Effectiveness against variants
The efficacy of the Novavax vaccine is 93% effective compared to current variants, according to the results of the Prevent-19 study, after analyzing almost 30,000 patients from the United States and Mexico.
It is expected to be approved soon
At the moment, the company has announced its effectiveness and the results of its studies, but it is still pending approval by the US Food and Drug Regulatory Agency (FDA).
And if approved, it would then be the fourth American vaccine, after those of Pfizer, Moderna and Janssen.
Also in Europe, but later
Once it is approved in the United States, it is expected that the company will also request it from the European Medicines Agency (EMA). Although agency sources have reported that surely it will not be until autumn when it is possible that it will already be approved in Europe.
How many doses could they get?
Step by step, because first it is important that it is approved, but everything indicates that it is possible that it is. Currently, the EU has not closed an agreement with Novavax for the purchase of 200 million doses. Of these doses, a total of 20 would come to Spain.
When it comes to Europe, it is expected that, in autumn, there will be 70% of the population vaccinated and that group immunity that is so much expected. In this case, in Europe there would already be five vaccines: Pfizer, Moderna, AstraZeneca and Janssen, along with the latter Novavax.
In the same way as the trial with the rest of the vaccines, the number of adverse reactions is rather low and among the most prominent are pain and tenderness at the puncture site, headaches and muscle aches.